Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release.
Angiotensin (Ang) II and Ang III are two peptide effectors of the brain renin-angiotensin system that participate in the control of blood pressure and increase water consumption and vasopressin release. In an attempt to delineate the respective roles of these peptides in the regulation of vasopressin secretion, their metabolic pathways and their effects on vasopressin release were identified in vivo. For this purpose, we used recently developed selective inhibitors of aminopeptidase A (APA) and aminopeptidase N (APN), two enzymes that are believed to be responsible for the N-terminal cleavage of Ang II and Ang III, respectively. Mice received [3H]Ang II intracerebroventricularly (i.c.v.) in the presence or absence of the APN inhibitor, EC33 (3-amino-4-thio-butyl sulfonate) of the APN inhibitor, EC27 (2-amino-pentan-1,5-dithiol). [3H]Ang II and [3H]Ang III levels were evaluated from hypothalamus homogenates by HPLC. EC33 increased the half-life of [3H]Ang II 2.6-fold and completely blocked the formation of [3H]Ang III, whereas EC27 increased the half-life of [3H]Ang III 2.3-fold. In addition, the effects of EC33 and EC27 on Ang-induced vasopressin release were studied in mice. Ang II was injected i.c.v. in the presence or absence of EC33, and plasma vasopressin levels were estimated by RIA. While vasopressin levels were increased 2-fold by Ang II (5 ng), EC33 inhibited Ang II-induced vasopressin release in a dose-dependent manner. In contrast, EC27 injected alone increased in a dose-dependent manner vasopressin levels. The EC27-induced vasopressin release was completely blocked by the coadministration of the Ang receptor antagonist (Sar1-Ala8) Ang II. These results demonstrate for the first time that (i) APA and APN are involved in vivo in the metabolism of brain Ang II and Ang III, respectively, and that (ii) the action of Ang II on vasopressin release depends upon the prior conversion of Ang II to Ang III. This shows that Ang III behaves as one of the main effector peptides of the brain renin-angiotensin system in the control of vasopressin release.
Zini
S
S
Institut National de la Santé et de la Recherche Médicale, Unité 36, Collège de France, Paris.
Fournie-Zaluski
M C
MC
Chauvel
E
E
Roques
B P
BP
Corvol
P
P
Llorens-Cortes
C
C
D000595:Amino Acid Sequence; D000626:Aminopeptidases / Q000037:antagonists & inhibitors*; D000804:Angiotensin II / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D000805:Angiotensin III / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D018826:CD13 Antigens / Q000037:antagonists & inhibitors*; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology; D043384:Glutamyl Aminopeptidase; D007276:Injections, Intraventricular; D007700:Kinetics; D008297:Male; D051379:Mice; D011480:Protease Inhibitors / Q000494:pharmacology*; D012504:Saralasin / Q000494:pharmacology; D013379:Substrate Specificity; D013438:Sulfhydryl Compounds / Q000494:pharmacology; D013451:Sulfonic Acids / Q000494:pharmacology; D013997:Time Factors; D014667:Vasopressins / Q000378:metabolism*
C101968:EC 33; D011480:Protease Inhibitors; D013438:Sulfhydryl Compounds; D013451:Sulfonic Acids; D014667:Vasopressins; D000804:Angiotensin II; D000805:Angiotensin III; C101969:EC 27; D000626:Aminopeptidases; D018826:CD13 Antigens; D043384:Glutamyl Aminopeptidase; D012504:Saralasin